Appearance of strong transplantation antigens in non-immunogenic lymphoma following drug-treatment in vivo.
A chemically induced lymphosarcoma line (LSBM-1) of C57BL/10 (H-2b) origin lacks detectable TATA and is scarcely immunogenic for H-2-incompatible congenic recipients. New antigenic specificities, defined as drug-mediated tumor antigen(s) (DMTA) were found in a subline (LBD-1) obtained by in vivo treatment of LSBM-1 with the anti-neoplastic agent dimethyl-1-triazeno-imidazole-carboxamide (DTIC) over several transplant generations. It was concluded that the presence of detectable TATA is not a prerequisite for the induction of new antigenic specificities (DMTA).
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D003606:Dacarbazine; D005260:Female; D006649:Histocompatibility Antigens / Q000276:immunology*; D008223:Lymphoma / Q000139:chemically induced / Q000276:immunology*; D008297:Male; D051379:Mice; D008806:Mice, Inbred AKR; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D014181:Transplantation Immunology; D014407:Tumor Cells, Cultured / Q000276:immunology*
D000951:Antigens, Neoplasm; D006649:Histocompatibility Antigens; C029237:tumor-associated transplantation antigen; D003606:Dacarbazine